AngioDynamics Q3 net sales up 9% but guides down; adjusted EPS loss $0.03 vs prior guidance for profit

ANGIODYNAMICS INC

2023-Q3 EPS reported -$0.79 revenue$247,678,000

Q3 net sales $80.7M (+9.1% YoY); GAAP loss per share $0.24 vs $0.13 loss last year; adjusted loss per share $0.03.
Med Tech sales $22.9M (+16.6%); Auryon +42.8% to $10.4M; AngioVac -15.7% to $5.5M.
Gross margin 50.2%, down 200 bps YoY; adjusted EBITDA $4.3M vs $6.7M.
FY2023 guidance cut: net sales now $338-342M (from $342-348M); adjusted EPS now loss $0.06 to loss $0.01 (from profit $0.01-0.06).
Cash $30.1M; total debt $50M; generated $1.4M operating cash in Q3.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ANGIODYNAMICS INC reported the third quarter of fiscal year 2023, which ended February 28, 2023 results: revenue $80.7 million, net income net loss of $9.5 million, or a loss per share of $0.24, EPS loss per share of $0.24. Guidance lowered.

Period: the third quarter of fiscal year 2023, which ended February 28, 2023
Revenue: $80.7 million
Net income: net loss of $9.5 million, or a loss per share of $0.24
EPS: loss per share of $0.24
Guidance: lowered
Result: reported results

Exact text from the filing

Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Fiscal Year 2023 Third Quarter Highlights • Net sales of $80.7 million increased 9.1% compared to the prior-year quarter o Med Tech net sales of $22.9 million increased 16.6% o Med Device net sales of $57.8 million increased 6.4% • Gross margin of

View on SEC.gov

Browse all earnings releases →

ANGIODYNAMICS INC filing history →

Source: SEC EDGAR

accession 0000914121-23-000149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.